Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by canadapieton Jul 10, 2022 12:58pm
185 Views
Post# 34813830

RE:RE:Few points that support me not to sell THTX

RE:RE:Few points that support me not to sell THTX
Maybe our new member Jane can also analyze some of the points below???
Or any other message board member human and civilised????




RE:Few points that support me not to sell THTX
Few points that support me not to sell THTX
1. Big shareholders barely sold the shares, furthermore, Morgan Stanley is accumulating shares significantly. Big shareholders shuch as Soleus and ALgh capital management bought a lot when the fast track designation was granted, meaning they are insertested in future of SORT1 techiqure.

2. In the past two years, no insider sold the shares. Instead, insiders bought a bunch of shares when the fast track designation was granted. I am wondering if to sell the shars is prohibited for insiders. If not, they are seemingly confident in the company's future.

3. The short interest achieves the historical low. 

4. The members of senior management team barely quit. Typically, if they are not optimistic about company's future, they will quit instead of staying in the company thay are pessimistic with. This is consistent to the point 2...they are seemingly confident about company's future. 

5. They have TH1902 which is potentially a game changer for treating cancer. Biotech companies which have a bunch of cash in China are eager to pay TH i order to obtain the right of SORT1 technique/TH1902. I actually went through all the literature about TH1902 and SORT1, i am confident that it will probably do its work.

6. And Egrifta, the revenue increases due to the more demand of EGRIFTA. EGRIFTA is potentially to treat NASH, cognitive impairment and neurodegernation. I just dont understand WHY they always have excuse to postpone the trial of NASH.

Despite all the points which may ideally drive the SP up, the SP somehow just nosedived anyway. I dont agree someone said that THTX doesnt care about investors. The insiders probably own more than you do (Dawn owns 273600 shares and Paul owns 111200 shares). However, the financial status and plan are my conserns, so far they dont have detailed plan to overcome the budget shortage in the future. Although the budget shortage is disturbing, cash will flow in if TH1902 works and actually i am confident to its performance. SO I personally dont see any signal telling me that i should sell THTX. But it is testing my nerves and patience honestly. 

<< Previous
Bullboard Posts
Next >>